Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s117, 2023. DOI: 10.25251/skin.7.supp.117. Disponível em: https://skin.dermsquared.com/skin/article/view/1969. Acesso em: 17 apr. 2026.